Galan Lithium Limited (ASX:GLN): How Is Hombre Muerto West Progressing Towards First Sales?

Aditi Sarkar

28 October 2026 08:49 PM AEDT

Galan Lithium Limited (ASX:GLN): How Is Hombre Muerto West Progressing Towards First Sales?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Galan Lithium targets first lithium chloride concentrate sales from Hombre Muerto West in Q4 CY2026.
Its September update moved the initial 4ktpa LCE throughput target to H1 CY2027.
Nanofiltration recorded sulphate rejection of at least 98% over more than three months.
Earthworks began for an expansion to 5.2ktpa, with higher output targeted for H2 CY2027.
FY26 cash was A$35.5 million, while the group reported a statutory loss of A$25.1 million.

Galan Lithium Limited (ASX:GLN) is developing lithium brine assets in Argentina, led by the Hombre Muerto West (HMW) operation in Catamarca. The company is progressing from commissioning towards commercial lithium chloride concentrate sales. Its September 2026 project update provided newer production targets than those in the June quarterly report, while the FY26 annual report outlined the financial position supporting this transition.

Hombre Muerto West Moves Through Its Initial Ramp-Up

On 24 September 2026, Galan Lithium (ASX:GLN) stated that first lithium chloride concentrate sales remained scheduled for Q4 CY2026. Its nanofiltration plant, which removes impurities from concentrated brine, was operating in line with the current evaporation rate. Over more than three months of data, the plant achieved sulphate rejection of at least 98%. The company said these results supported further concentration towards its targeted lithium content of 6%.

The September announcement also described one of the Puna region’s most severe winters in recent history. Snowfall and wind led to brief safety-related suspensions, while colder conditions affected evaporation. Authium planned an additional pressure-vessel skid to improve capacity and winter resilience.

Production Targets and Expansion Timing

Galan Lithium (ASX:GLN) now expects its initial annualised throughput rate of 4,000 tonnes of lithium carbonate equivalent (LCE) in H1 CY2027. This supersedes the earlier June-quarter expectation of reaching a stabilised 4,000-tonne rate during 2026. The revised schedule distinguishes first sales, which remain targeted for Q4 CY2026, from sustained throughput, which is expected later.

Earthworks have commenced for the first-stage expansion from 4,000 to 5,200 tonnes per annum LCE. The September update places the higher production volumes in H2 CY2027.

FY26 Accounts Show Liquidity Alongside Losses

The annual report released on 30 September 2026 recorded A$35.5 million of cash and cash equivalents at 30 June 2026, compared with A$4.4 million a year earlier. Galan Lithium (ASX:GLN) reported an FY26 loss after tax of A$25.1 million, compared with a restated A$23.6 million loss in FY25. Net cash used in operating activities was A$3.1 million, while investing activities used A$29.8 million. Net financing inflows were A$65.0 million, reflecting reliance on external funding during development.

The accounts attributed the increase in cash partly to equity placements, including a A$40 million institutional placement announced in January 2026. Expenditure on commissioning, expansion and working capital remains relevant as production develops.

Execution and Commercial Risks

The principal uncertainties for Galan Lithium (ASX:GLN) concern achieving target product concentration, maintaining plant operation through variable weather, and completing initial deliveries under commercial arrangements. Delays to sales would defer operating receipts. Expansion works introduce construction and cost risks, while lithium market conditions can affect realised proceeds. The FY26 loss also shows that commercial-scale earnings have not yet been demonstrated. Reported process results cannot alone establish future production rates or profitability.

Key Insights

Galan Lithium (ASX:GLN) has reported measurable progress in impurity removal and started expansion earthworks at HMW. Its September 2026 timetable separates Q4 CY2026 first sales from H1 CY2027 initial throughput and H2 CY2027 expansion volumes. FY26 cash increased following financing activity, although the company remained loss-making. The significance of the next updates will depend on actual sales, operating reliability, spending and delivery against those disclosed targets.

FAQs

Q: Has Galan confirmed its first lithium chloride concentrate sale?

A: No. As of its 24 September 2026 update, first sales were targeted for Q4 CY2026.

Q: When does Galan expect to reach 4ktpa LCE throughput?

A: The company targeted H1 CY2027 in its September project update.

Q: What did the nanofiltration plant achieve?

A: Galan reported sulphate rejection of at least 98% over more than three months of data.

Q: How much cash did Galan report at FY26 year-end?

A: Cash and cash equivalents were A$35.5 million at 30 June 2026.

Q: When are expanded HMW volumes expected?

A: Higher output from the planned 5.2ktpa expansion was targeted for H2 CY2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.